Arcturus Therapeutics Holdings Inc.
ARCT
4
|
$30.01
2.39%
110K
|
Health Technology
(0.0% 1d) (-11.5% 1m) (6.0% 1y) (0.0% 2d) (0.0% 3d) (-7.9% 7d) (50.5% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 807,726,442
http://www.arcturusrx.com
Sec Filling | Patents | 118 employees
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
respiratory liver treatment respiratory diseases
add to watch list Paper trade email alert is off
Press-releases
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
Published: 2024-02-26 (Crawled : 14:30) - arcturusrx.com
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: -0.03%
H: 9.97%
C: 9.44%
conference global therapeutics
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
Published: 2024-02-20 (Crawled : 15:30) - biospace.com/
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: -1.73%
H: 1.93%
C: -0.19%
report year update therapeutics financial results
Seeking Alpha Service: Expert Opinions and Smart Investing Converge
Published: 2024-02-13 (Crawled : 19:00) - prnewswire.com
SLVM 4 | $57.19 -0.82% 37K
|
Manufacturing
|
| O: 0.26%
H: 0.55%
C: -0.31%
ZYME | $8.99 -1.1% 85K
|
Health Technology
|
| O: 1.06%
H: 1.23%
C: 0.09%
YALA | $4.745 -0.11% 150K
|
Technology Services
|
| O: 0.42%
H: 2.33%
C: 1.9%
VST 4 d | $66.315 -2.79% 3.4M
|
Utilities
|
| O: 0.75%
H: 1.06%
C: -0.58%
TNK | $56.725 -1.37% 87K
|
Transportation
|
| O: 0.84%
H: 0.07%
C: -1.45%
SYF | $40.03 -1.09% 990K
|
Finance
|
| O: 1.27%
H: 0.55%
C: 0.49%
STNG | $70.325 -0.35% 190K
|
Transportation
|
| O: 0.04%
H: 2.1%
C: -1.79%
RGA | $181.26 -0.21% 43K
|
Finance
|
| O: 0.26%
H: 1.74%
C: 1.58%
PGTI | $41.99 -0.0% 2.2M
|
Producer Manufacturing
|
| O: 0.1%
H: 0.12%
C: -0.07%
PARR 4 | $32.825 -1.75% 130K
|
Energy Minerals
|
| O: 0.96%
H: 0.63%
C: 0.2%
PAM | $41.42 -2.43% 110K
|
Utilities
|
| O: 0.3%
H: 2.14%
C: 1.06%
PAGS | $11.945 -2.41% 1.1M
|
Commercial Services
|
| O: 1.63%
H: 1.6%
C: 1.15%
EPRT | $24.815 -1.41% 87K
|
Finance
|
| O: 0.17%
H: 0.37%
C: -0.21%
ENIC | $2.855 -1.89% 48K
|
Utilities
|
| O: 1.85%
H: 2.55%
C: 1.82%
DESP | $11.65 0.26% 210K
|
Consumer Services
|
| O: 0.99%
H: 2.2%
C: 1.59%
DHI | $145.125 -2.65% 630K
|
Consumer Durables
|
| O: 1.29%
H: 1.46%
C: 0.89%
CNC | $71.94 -1.07% 900K
|
Health Services
|
| O: 0.26%
H: 0.83%
C: 0.77%
ASC | $15.725 -0.41% 88K
|
Transportation
|
| O: 0.67%
H: 0.41%
C: -1.57%
STNE | $15.36 -4.72% 1.6M
|
Technology Services
|
| O: 1.65%
H: 1.85%
C: 1.27%
SPOK | $15.17 -1.62% 57K
|
Communications
|
| O: 0.93%
H: 0.49%
C: -0.06%
RCMT | $19.12 0.32% 24K
|
Industrial Services
|
| O: 0.7%
H: 1.71%
C: 0.63%
PGTI | $41.99 -0.0% 2.2M
|
Producer Manufacturing
|
| O: 0.1%
H: 0.12%
C: -0.07%
MGNX 4 | $17.14 1.18% 220K
|
Health Technology
|
| O: -4.21%
H: 6.5%
C: 3.07%
LMB 4 | $39.12 0.26% 16K
|
Miscellaneous
|
| O: 1.85%
H: 4.24%
C: 4.24%
LI | $28.445 -0.54% 2.5M
|
Producer Manufacturing
|
| O: 2.58%
H: 0.2%
C: -1.53%
ITRN | $26.34 0.73% 29K
|
Electronic Technology
|
| O: 1.74%
H: 2.41%
C: 2.33%
FCNCA | $1522.38 -0.99% 22K
|
Finance
|
| O: 0.87%
H: 1.12%
C: 0.01%
FITB | $34.025 -1.72% 1.7M
|
Finance
|
| O: 1.28%
H: 1.04%
C: 0.81%
ESEA | $33.75 -1.46% 7.6K
|
Transportation
|
| O: 1.12%
H: 1.28%
C: -3.77%
CCAP | $16.945 -0.09% 23K
|
Finance
|
| O: 0.37%
H: 0.06%
C: -0.12%
BWAY | $5.21 -1.14% 19K
|
Health Technology
|
| O: 2.18%
H: 6.4%
C: -0.3%
BELFB | $57.935 -0.78% 6.8K
|
Electronic Technology
|
| O: 1.22%
H: 5.5%
C: 4.52%
BELFA | $68.98 -0.89% 1K
|
Electronic Technology
|
| O: 1.03%
H: 4.49%
C: 4.04%
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: 2.14%
H: 0.58%
C: -2.88%
ALKS | $23.92 -0.42% 190K
|
Health Technology
|
| O: 0.99%
H: 1.93%
C: 1.78%
SILV | $6.97 -3.33% 660K
|
Non-Energy Minerals
|
| O: 0.59%
H: 1.56%
C: 0.2%
smart
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
Published: 2024-02-11 (Crawled : 00:00) - prnewswire.com
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: 0.86%
H: 4.25%
C: 4.1%
csl112 trial results
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Published: 2024-02-05 (Crawled : 13:30) - prnewswire.com
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
PassPort Technologies Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA delivery systems
Published: 2024-01-05 (Crawled : 19:00) - prnewswire.com
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
| Email alert
Add to watchlist
transdermal mrna research therapeutics
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Published: 2023-12-04 (Crawled : 14:30) - biospace.com/
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: -0.36%
H: 2.1%
C: -3.19%
conference therapeutics
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
Published: 2023-11-28 (Crawled : 13:00) - prnewswire.com
QURE | $4.755 0.32% 120K
|
Health Technology
|
| O: -3.42%
H: 3.24%
C: 2.95%
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: -0.93%
arct-154 covid vaccine approved mrna
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
Published: 2023-11-27 (Crawled : 14:30) - biospace.com/
ARCT 4 | $30.01 2.39% 110K
|
Health Technology
|
| O: 2.89%
H: 6.75%
C: 4.88%
arct-032 fda drug treatment fibrosis designation therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001193805-24-000426 | 4 | 2024-03-21 | 2024-03-19 | Sell | S | 8565 | 490883 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 51% | 49% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
PRSO | $1.99 56.69% 52M
|
Manufacturing
PALI | $6.5 56.25% 22M
|
Manufacturing
JAGX | $0.1767 48.74% 430M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
DYNT | $0.5255 41.87% 18M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
MCBC | $13.795 38.92% 820K
|
Finance
Last 48 Hours Insiders Buying
TPL P 12 | $588.26 0.75% 12K
|
Miscellaneous
|
16:01
HNRA | $2.617 10.89% 260K
|
n/a
|
15:02
TGEN | $0.67 16K
|
Utilities
|
14:30
RMCF | $3.6492 9.1K
|
Consumer Non-Durables
|
20:10